Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage biotechnology company developing cell therapies and immunotherapies for cancer and other incurable diseases. Through these filings, investors can review how Arcellx reports its financial condition, collaboration revenue, research and development spending, and progress toward potential commercialization.
Arcellx uses periodic and current reports to disclose key information. For example, the company files Form 8-K to furnish press releases announcing quarterly financial results, as reflected in 8-K filings tied to results for quarters ended June 30 and September 30, 2025. These filings describe collaboration revenue associated with its partnership activities, research and development expenses related to clinical and preclinical programs, general and administrative expenses, and net losses as the company advances its pipeline.
In addition to 8-Ks, investors can use this page to find Arcellx’s annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These documents typically provide detailed discussions of the company’s lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), its Phase 2 iMMagine-1 and Phase 3 iMMagine-3 studies in relapsed or refractory multiple myeloma, regulatory designations, and its global strategic collaboration with Kite, a Gilead Company.
Stock Titan enhances these filings with AI-powered summaries that highlight key points such as revenue trends, R&D and G&A dynamics, cash runway disclosures, and material clinical or regulatory updates. Users can also review insider transaction reports on Form 4, proxy statements on Form DEF 14A, and other relevant submissions as they appear in the SEC’s EDGAR system. Together, these resources help investors and researchers quickly interpret Arcellx’s regulatory disclosures and understand the financial and operational context behind ACLX.
Arcellx, Inc. President, CEO and Chairman Rami Elghandour reported a bona fide gift of 198,000 shares of common stock on February 11, 2026. The shares were transferred for no consideration to a spousal lifetime access non‑grantor trust benefiting his spouse.
After the transfer, he directly held 365,967 common shares, and an additional 198,000 shares were held indirectly by the trust. He states he may be deemed to retain Section 16 beneficial ownership but expressly disclaims beneficial ownership except to the extent of any pecuniary interest.
Arcellx, Inc. insider Rami Elghandour reported a large family estate-planning transfer of company stock. On February 11, 2026, the reporting person’s spouse made a bona fide gift of 218,500 shares of Arcellx common stock, transferring them for no consideration to a spousal lifetime access non-grantor trust in which he is a beneficiary.
Following this transaction, the filing shows 563,967 shares of Arcellx common stock held directly and 218,500 shares held indirectly through the trust. The footnote states he may be deemed to continue to have Section 16 beneficial ownership of the transferred shares, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
FMR LLC
FMR LLC has sole voting power over 3,561,162.00 shares and sole dispositive power over 3,563,728.46 shares. Abigail P. Johnson reports sole dispositive power over the same 3,563,728.46 shares and no voting power. The securities are certified as held in the ordinary course of business, without a purpose of changing or influencing control of Arcellx.
Arcellx, Inc. director David Charles Lubner reported option exercises and share sales in the company’s stock. On January 20, 2026, he exercised a stock option for 6,000 shares of common stock at an exercise price of
ACLX filed a notice of proposed sale under Rule 144 for 15,000 shares of its common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,034,100 based on the figures provided.
The shares to be sold were acquired on 01/20/2026 through the cash exercise of stock options granted by the issuer on the same date. ACLX reports that 57,822,871 shares of common stock were outstanding, giving context for the size of this planned sale.
A shareholder named Christopher Heery filed a Rule 144 notice to sell 5,882 shares of common stock through E-TRADE Financial Corporation, with an aggregate market value of $402,997.10. The shares relate to a company that had 57,917,336 shares outstanding, and the sale is expected to occur around 01/14/2026 on the NASDAQ exchange.
The securities to be sold were acquired on 01/06/2026 as restricted stock units from the issuer, with 13,064 shares acquired on that date. Over the prior three months, the same shareholder reported additional common stock sales of 340 shares on 11/17/2025 for $30,600.00, 6,131 shares on 01/12/2026 for $393,286.14, and 7,437 shares on 01/13/2026 for $487,213.08.
Arcellx, Inc. chief medical officer Christopher Heery reported equity award activity and a related share sale. On 01/06/2026, he acquired 13,064 shares of common stock at $0.00 per share through the vesting and settlement of previously reported restricted stock units, each RSU converting into one share. On 01/14/2026, he sold 5,882 shares of common stock at a weighted average price of $68.5136 per share in a broker-assisted transaction to cover tax withholding obligations tied to that RSU vesting.
After these transactions, Heery directly held 23,749 shares of Arcellx common stock.
A shareholder of ACLX has filed a notice to sell 7,437 shares of common stock through E-TRADE Financial Corporation on or around 01/13/2026 on NASDAQ. The filing shows these shares are part of 57,917,336 common shares outstanding. The seller, Christopher Heery, acquired 16,520 shares as restricted stock units from the issuer on 01/03/2026, with payment noted as N/A. Over the prior three months, he sold 340 shares of common stock on 11/17/2025 for gross proceeds of 30,600.00 and 6,131 shares on 01/12/2026 for gross proceeds of 393,286.14. By signing, the seller represents that he is not aware of any undisclosed material adverse information about ACLX.
Arcellx, Inc.’s Chief Medical Officer Christopher Heery reported RSU vesting and a related share sale. On 01/03/2026 he acquired 16,520 shares of Common Stock at an exercise price of $0, reflecting settlement of previously granted restricted stock units, each representing one share.
On 01/13/2026 he sold 7,437 shares of Common Stock at a weighted average price of $65.512 per share in a broker-assisted transaction to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he directly beneficially owns 29,631 shares of Arcellx Common Stock.
Arcellx, Inc. chief medical officer Christopher Heery reported two equity transactions in company stock. On 01/02/2026, he exercised options coded "M" for 13,021 shares of common stock at a price of $0 per share, increasing his directly held position to 13,615 shares.
On 01/12/2026, he executed a broker-assisted sale coded "S" of 6,131 common shares at a weighted average price of $64.1471 per share to cover tax withholding obligations tied to restricted stock unit vesting. Following these transactions, he directly owned 37,068 shares of Arcellx common stock.